Exiburn
Natural health product licensed in Canada
- Other names
- Bonnevie EXIBURN, PurVit CLA+Carnitine
- Licence holder
- Cambridge Pharma Inc.
- NPN or DIN-HM
- 80088503
- Status
- Active licence
- Licence date
- 28 September 2018
- Revision date
- Not provided
- Form
- Capsule, molle
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| L-Carnitine Source : L-tartrate de carnitine | 250 mg | Not calculated |
Non-medicinal ingredients
Glycérine, Huile de fève de soja, Gélatine, Eau purifiée, Cire d'abeille jaune, Lécithine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 2 Capsule | 3 days |
Uses authorised in Canada
May help to support a modest improvement to body composition when used with a program of reduced intake of dietary calories and increased physical activity. May help to support a modest reduction in fat mass when used with a program of reduced intake of dietary calories and increased physical activity. Helps support fat metabolism. Aids in the muscle recovery process by reducing muscle tissue damage associated with a resistance training regimen. Helps support muscle tissue repair in individuals involved in resistance training. Antioxidant. Workout support/supplement.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are obese or have cardiovascular disease (CVD) risk factors (e.g. high blood pressure, high cholesterol and/or triglycerides). Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if your goal is to achieve weight loss. If you have a liver disease, a kidney disease, or a seizure disorder, consult a healthcare practitioner prior to use. Consult a health care practitioner prior to use if you are taking lithium. Consult a health care practitioner prior to use if you have high blood pressure, glaucoma, and/or detrusor instability (overactive bladder syndrome). Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. Consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, maté) is not recommended. This product is not intended as a substitute for sleep.
- Contre-indications
Do not use if you have CVD, diabetes, metabolic syndrome or insulin resistance.
- Effets indésirables connus
Some people may experience gastrointestinal upset. Hypersensitivity/allergy is known to occur, in which case, discontinue use.
Source
Official Health Canada record, licence 80088503
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.